BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Mise à jour : Il y a 4 ans
Référence : NCT01354431

Femme et Homme

Extrait

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.


Critère d'inclusion

  • Renal Cell Carcinoma